A comparison of the potency of the oxime HLö-7 and currently used oximes (HI-6, pralidoxime, obidoxime) to reactivate nerve agent-inhibited rat brain acetylcholinesterase by in vitro methods
- PMID: 16259317
A comparison of the potency of the oxime HLö-7 and currently used oximes (HI-6, pralidoxime, obidoxime) to reactivate nerve agent-inhibited rat brain acetylcholinesterase by in vitro methods
Abstract
(1) The efficacy of the oxime HLö7 and currently used oximes (pralidoxime, obidoxime, HI-6) to reactivate acetylcholinesterase inhibited by various nerve agents (sarin, tabun, cyclosarin, VX) was tested by in vitro methods. (2) Both H oximes (HLö-7, HI-6) were found to be more efficacious reactivators of sarin and VX-inhibited acetylcholinesterase than pralidoxime and obidoxime. On the other hand, their potency to reactivate tabun-inhibited acetylcholinesterase is very low and does not reach the reactivating efficacy of obidoxime. In the case of cyclosarin, the oxime HI-6 was only found to be able to sufficiently reactivate cyclosarin-inhibited acetylcholinesterase in vitro. (3) Thus, the oxime HLö-7 does not seem to be more efficacious reactivator of nerve agent-inhibited acetylcholinesterase than HI-6 according to in vitro evaluation of their reactivation potency and, therefore, it is not more suitable to be introduced for antidotal treatment of nerve agent-exposed people than HI-6.
Similar articles
-
In vitro potency of H oximes (HI-6, HLö-7), the oxime BI-6, and currently used oximes (pralidoxime, obidoxime, trimedoxime) to reactivate nerve agent-inhibited rat brain acetylcholinesterase.J Toxicol Environ Health A. 2006 Aug;69(15):1431-40. doi: 10.1080/15287390500364283. J Toxicol Environ Health A. 2006. PMID: 16766478
-
A comparison of the efficacy of a bispyridinium oxime--1,4-bis-(2-hydroxyiminomethylpyridinium) butane dibromide and currently used oximes to reactivate sarin, tabun or cyclosarin-inhibited acetylcholinesterase by in vitro methods.Pharmazie. 2004 Oct;59(10):795-8. Pharmazie. 2004. PMID: 15544060
-
A comparison of reactivating efficacy of newly developed oximes (K074, K075) and currently available oximes (obidoxime, HI-6) in cyclosarin-and tabun-poisoned rats.J Enzyme Inhib Med Chem. 2007 Jun;22(3):297-300. doi: 10.1080/14756360601114361. J Enzyme Inhib Med Chem. 2007. PMID: 17674811
-
Unequal efficacy of pyridinium oximes in acute organophosphate poisoning.Clin Med Res. 2007 Mar;5(1):71-82. doi: 10.3121/cmr.2007.701. Clin Med Res. 2007. PMID: 17456837 Free PMC article. Review.
-
The development of new oximes and the evaluation of their reactivating, therapeutic and neuroprotective efficacy against tabun.Mini Rev Med Chem. 2008 Oct;8(11):1134-43. doi: 10.2174/138955708785909871. Mini Rev Med Chem. 2008. PMID: 18855728 Review.
Cited by
-
Differential binding of bispyridinium oxime drugs with acetylcholinesterase.Acta Pharmacol Sin. 2010 Mar;31(3):313-28. doi: 10.1038/aps.2009.193. Epub 2010 Feb 8. Acta Pharmacol Sin. 2010. PMID: 20140002 Free PMC article.
-
Autoinjector device for rapid administration of drugs and antidotes in emergency situations and in mass casualty management.J Int Med Res. 2020 May;48(5):300060520926019. doi: 10.1177/0300060520926019. J Int Med Res. 2020. PMID: 32436421 Free PMC article. Review.
-
Advances in toxicology and medical treatment of chemical warfare nerve agents.Daru. 2012 Nov 28;20(1):81. doi: 10.1186/2008-2231-20-81. Daru. 2012. PMID: 23351280 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical